Preparation, optimization and characterization of biocompatible nanoalbumin-ofloxacin(BSANP-OF) conjugate and evaluation of control release, anti bacterial activity against clinical isolate of Pseudomonas aeruginosa

Asian Journal of Pharmaceutical and Clinical Research

Volumn 6, Issue 3, 2013, Pages 235-239

  Karthick Raja Namasivayam, S ^a   George Robin, A T ^a  

^a SATHYABAMA UNIVERSITY   (India)

Author keywords

Anti bacterial activity; Control release; Nano albumin; Nanosphere; Ofloxacin; Pseudomonas aeruginosa

Indexed keywords

BOVINE SERUM ALBUMIN NANOPARTICLE; NANOCONJUGATE; OFLOXACIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; CHEMICAL PARAMETERS; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSS LINKING TIME; DISK DIFFUSION; DRUG COATING; DRUG CONJUGATION; DRUG DOSAGE FORM COMPARISON; DRUG ENTRAPMENT EFFICIENCY; DRUG LOADING EFFICIENCY; DRUG STABILITY; DRUG SYNTHESIS; ENCAPSULATION; ETHANOL ALBUMIN RATIO; GROWTH INHIBITION; IN VITRO STUDY; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PH; PROCESS OPTIMIZATION; PSEUDOMONAS AERUGINOSA; SCANNING ELECTRON MICROSCOPY;

EID: 84879944266     PISSN: 09742441     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. K. Zwiorek J. Kloeckner C. Wagner E, Coester Gelatin nanoparticles as a new and simple gene delivery system. J. Pharm. Pharm. Sci. 2004,7;28-32
2. R. Srilatha, C. Aparna, P. Srinivas,. M. Sadanandam. Formulation, evaluation characterization of glipizide nanoemulsion. Asian Journal of Pharmaceutical and Clinical Research 2013,6;66-72
3. A. Amzallag, C. Vaillant, M. Jacob, M. Unser, J. Bednar, A. Stasiak, J.H. Maddocks, Nucleic Acids Res 2006,12;17-23
4. M.A. Arangoa, A. Campanero, J.A. Renedo, M. J, Ponchel.J.M. Irache. Pharm. Res,2001,18; 1527-1530
5. L. Betancor, H.R. Luckarift Trends Biotechnol, 2008, 26; 572-576
6. K. Bouchemal, S. Briançon, E. Perrier, H. Fessi. Int. J. Pharm 2004,280;251-257
7. P. Couvreur, R. Gref, K. Andrieux, C. Malvy. Prog. Solid State Chem 2006,34;235-238
8. 8.N. Desai, V. Trieu, Z. Yao, L. Louie, A. Ci,. Yang, C., Tao, T., De, B., Beals, D.,. Dykes, P., Noker, R., Yao, E., Labao, M., Hawkins, P. and Soon-Shiong, Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel, Clin. Cancer Res, 2006, 12, 1317-1324.
9. Dunne., M., Corrigan., O.I., and Ramtoola, Z. Influence of particle size and dissolution conditions on the degradation properties of polylactide-coglycolide particles. Biomaterials, 2001, 21,1659-1668.
10. Fattal., E, Vauthier., C, Aynie., I, Nakada., Y, Lambert., G, Malvy., C. and Couvreur., P Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides, J. Control. Release, 1998, 53, 137-143.
11. Ezpeleta., I, Irache., J. M, Stainmesse., S, Chabenat., C, Popineau., Y. and Orecchionic., A.M. Preparation of Ulex europaeus lectin-gliadin nanoparticles conjugates and their interaction with gastrointestinal mucus. Int. J. Pharm,1999, 191, 25-32.
12. Gelderblom., H, Verweij., J, Nooter., K, Sparreboom., A and Cremophor., E.L. The drawbacks and advantages of vehicle selection for drug formulation, Eur. J. Cancer,2001, 37, 1590-1598.
13. 13 Gradishar., W. J, Tjulandin., S, Davidson., N, H. Shaw., H, Desai., N, Bhar., P, Hawkins., M. and Shaughnessy., J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer, J. Clin. Oncol,2005, 23,7794-7803.
14. Guan, F.,. Feng, Q.L., Li, Z., Jiang, Z., Shen, S., Yu, J., Feng, J., Huang, Z., Yao, M. J and Hawkins, Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC), J. Clin. Oncol.2007, 25, 1038.
15. Rubino, O P., Kowalsky., R and Swarbrick, J. Albumin Microspheres as a Drug Delivery System: Relation Among Turbidity Ratio, Degree of Cross-linking, and Drug Release Pharm. Res, 1993,10, 1059-1075
16. Lin, W., Garnett., M C, Davies., M C, Bignotti., F, Ferruti., P, Davis, S.S. and Illum., L Preparation of surface-modified albumin nanospheres, Biomaterials, 1997,18,559-565.
17. 17. Takahashi., K, Kato., H, Saito., T, Matsuyama., S. and Kinugasa., S. Precise Measurement of the Size of Nanoparticles by Dynamic Light Scattering with Uncertainty Analysis Part. Part. Syst. Charact,2008,.25, 31-38.
18. Breitenbach., M.A., Kamm., W, Hungere., K.D., Hund., H and Kissel, T. Oral and nasal administration of tetanus toxoid loaded nanoparticles consisting of novel charged biodegradable polyesters for mucosal vaccination. Proc. Intern. Symp. Control. Release. Bioact. Mater,1999, 26,348-349.
19. Jahanshahi., M, Sanati., M. H, Hajizadeh., S. and Babaei, Z. Gelatin nanoparticles fabrication and optimization of the particle size. Physica status solidi (a),2008a, 10,1002-1010.
20. John, T. A, Vogel, S. M, Tiruppathi., C, Malik, A. B and Minshall, R.D. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer, Am. J. Physiol. Lung Cell Mol. Physiol,2003,284, 187-196.
21. Kreuter., J, Ramge., P, Petrov., V, Hamm., S, Gelperina., S. E, Engelhardt., B, Alyautdin., R, von Briesen., H, Begley., D.J. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res,2000. 20: 409-416.